Charles River Labs Intl Aktie
164,40 €
Deine Einschätzung
Charles River Labs Intl Aktie
Was spricht für und gegen Charles River Labs Intl in den nächsten Jahren?
Pro
Kontra
Rendite von Charles River Labs Intl im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Charles River Labs Intl | 1,86 % | 9,86 % | 29,30 % | -5,03 % | -6,99 % | -18,99 % | -15,26 % |
| Ironwood Pharmaceuticals | 0,76 % | -2,21 % | 13,68 % | -63,66 % | -68,33 % | -86,86 % | -83,27 % |
| Novocure Ltd | 2,51 % | -0,17 % | 8,95 % | -20,07 % | -58,83 % | -83,36 % | -88,52 % |
| Iovance Biotherapeutics Inc. | 2,05 % | -1,64 % | 7,11 % | -79,35 % | -72,77 % | -79,33 % | -94,07 % |
Kommentare
News
Charles River Laboratories Schedules Second-Quarter 2025 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2025 financial results on Wednesday, August 6th, before the market opens. A conference call has been scheduled
Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a recycling program, developed in partnership with international recycling leader TerraCycle®, to give new life to
Charles River Laboratories to Present at William Blair and Jefferies Conferences
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the William Blair 45th Annual Growth Stock Conference on Tuesday, June 3rd, at 10:00 a.m. CT


